EP1337250A2 - Utilisation d'inhibiteurs de p38 pour le traitement de troubles dus a l'inhalation du tabac - Google Patents

Utilisation d'inhibiteurs de p38 pour le traitement de troubles dus a l'inhalation du tabac

Info

Publication number
EP1337250A2
EP1337250A2 EP01987743A EP01987743A EP1337250A2 EP 1337250 A2 EP1337250 A2 EP 1337250A2 EP 01987743 A EP01987743 A EP 01987743A EP 01987743 A EP01987743 A EP 01987743A EP 1337250 A2 EP1337250 A2 EP 1337250A2
Authority
EP
European Patent Office
Prior art keywords
smoke
alkyl
inhibitor
airway inflammation
induced airway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01987743A
Other languages
German (de)
English (en)
Inventor
Don E. Griswold
David C. Underwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1337250A2 publication Critical patent/EP1337250A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Definitions

  • the present invention relates to the use of a CSBP/p38 inhibitor in the treatment of smoke exposure related disorders which are CSBP/p38 mediated.
  • Pulmonary or airway inflammatory responses are thought to be orchestrated by macrophage, epithelial- and pulmonary vascular endothelial derived cytokines, such as TNF- and IL-l ⁇ which enhance the expression of vascular adhesion molecules (ICAM-1, E-selectin) and neutrophil chemotaxins or chemokines, such as IL-8, to generate the release of destructive oxidants and proteases [Warner et al., Am J. Respir Crit Care Med. 160:S1-S79 (1999)].
  • IAM-1 vascular adhesion molecules
  • chemokines such as IL-8
  • pro-inflammatory cytokines TNF- ⁇ , IFN- ⁇ , IL-4, IL-5 and IL-6) and chemokines (IL-8, RANTES, eotaxin) are capable of regulating or supporting chronic airway inflammation [Barnes et al., Pharmacol Rev. 50:515-596 (1998)].
  • the production and action of many of the potential mediators of airway inflammation have been shown to be dependent upon the stress induced MAP kinase or p38 kinase cascade.
  • a vaiiety of inflammatory mediators activate p38 MAPK which may then activate downstream targets of the MAPK system including other kinases or transcription factors, thus creating the potential for an amplified inflammatory process in the lung.
  • This invention is directed to the novel discovery of treatment, including prophylaxis, of smoke induced pathology resulting from acute and chronic inflammation in the lung.
  • the present invention relates to the use of a CSBP/p38 kinase inhibitor for the treatment, including prophylaxis, of the airway inflammation caused by inhalation of smoke, such as cigarette smoke, or other smoke of other natural extracts.
  • smoke such as cigarette smoke, or other smoke of other natural extracts.
  • IL-1, TNF, and other cytokines affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions. Thus inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
  • the present invention is directed to the treatment of inhaled smoke induced airway inflammation, lung chemokine production and cytokine production.
  • the invention may be directed to treatment of the airway induced inflammation which is secondary to other respiratory disorders such as viral infections that exacerbate asthma (induced by such infections), chronic bronchitis, chronic obstructive pulmonary disease, otitis media, and sinusitis.
  • a respiratory viral infection treated in conjunction with the smoke related airway inflammation may also be associated with a secondary bacterial infection, such as otitis media, sinusitis, or pneumonia.
  • treatment may include prophylaxis for use in a treatment group who may be susceptible to such airway inflammation. It may also include reducing the symptoms of, ameliorating the symptoms of, reducing the severity of, reducing the incidence of, or any other change in the condition of the patient, which improves the therapeutic outcome. Suitable patient populations for whom this may be prophylatically beneficial could be firemen who routinely inhale smoke in the course of their duties; use in the military, and by civilians in wartime exposure.
  • CSAID cytokine suppressive anti-inflammatory drug
  • smoke of natural causes such as plant extracts, natural plants products, synthetic material, chemically treated natural materials, or natural products such as oil and gas
  • the treatment including prophylaxis is related to cigarette smoke or synthetic/composites, such as occur in fires associated with burning buildings or homes.
  • Suitable CSAID compounds are well known in the art, and an assay for determining CBSP/p38 inhibition is also readily available using assays disclosed in the below noted patents or applications. For instance, see US Patents 5,716,972, US 5,686,455, US 5,656,644, US 5,593,992, US 5,593,991, US
  • Preferred compounds of this invention include those contained in WO 99/01131, and a representative genus is described below. Also preferred for use herein are the compounds disclosed in WO 99/61426 Scios, Inc.; and those compounds disclosed in WO 98/27098 containing the compound known as NX-745; (also known as 5-(2,6-Dichloro-phenyl)-2-(2,4-difluoro-phenylsulfanyl)-l ,7,8a- triaza-naphthalen-6-one), the Johnson & Johnson compound RWJ-68354 disclosed in WO 98/47899, RPR compound RPR-200765A, the Zeneca compound ZM 336372 disclosed in WO 99/15164; the Sugen compound SU 4984 disclosed in WO
  • Rl is 4-pyridyl, pyrimidinyl, 4-pyridazinyl, l,2,4-triazin-5-yl, quinolyl, isoquinolinyl, or quinazolin-4-yl ring, which ring is substituted with Y-Ra and optionally with an additional independent substituent selected from Ci-4 alkyl, halogen, hydroxyl, C ⁇ _4 alkoxy, Ci-4 alkylthio, C ⁇ _4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15, N(Rio)C(O)Rb or NHR a ; Y is oxygen or sulfur;
  • R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri , C(Z)ORi6, (CRioR20)vCORi2, SR5, SOR5, OR12, halo-substituted-Ci-4 alkyl, Ci-4 alkyl, ZC(Z)Ri2, NR ⁇ oC(Z)Ri6, or (CRioR2 ⁇ ) NRl ⁇ R20 and which, for other positions of substitution, is halogen, cyano, C(Z)NRi3Ri4, C(Z)OR3, (CRioR20)m"COR3, S(
  • Z is oxygen or sulfur; n is an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; v is 0, or an integer having a value of 1 or 2;
  • R 2 is -C(H) (A) (R 22 );
  • A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted C1 -10 alkyl; R22 is an optionally substituted CJ. ⁇ Q alkyl;
  • Ra is aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, heteroarylC ⁇ _6alkyl, wherein each of these moieties may be optionally substituted;
  • Rb is hydrogen, C ⁇ - alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi_4alkyl, heterocyclyl, or heterocyclylC ⁇ _4 alkyl, wherein each of these moieties may be optionally substituted;
  • R3 is heterocyclyl, heterocyclylCi-io alkyl or R ⁇ ;
  • R5 is hydrogen, Cj . _4 alkyl, C2-4 alke ⁇ yl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH;
  • R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-.7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylC ⁇ _4alkyl, heterocyclyl, aroyl, or Ci-io alkanoyl;
  • R7 and R17 is each independently selected from hydrogen or C ⁇ _4 alkyl or R7 and Rl7 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15;
  • R ⁇ is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl
  • Rl2 is hydrogen or Ri6
  • Rl3 and R1 is each independently selected from hydrogen or optionally substituted Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-C ⁇ _4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9 ;
  • Rl5 is Rio or C(Z)-Ci-4 alkyl;
  • Rl6 is C ⁇ _4 alkyl, halo-substituted-Ci-4 alkyl, or C3-.7 cycloalkyl
  • Rl8 is C ⁇ _ ⁇ o alkyl, C3-.7 cycloalkyl, heterocyclyl, aryl, aryl ⁇ _ ⁇ oalkyl, heterocyclyl, heterocy clyl-C 1 _ 1 oalkyl, heteroaryl or heteroaryl 1 _ 1 oalkyl
  • Rl6 is C ⁇ _4 alkyl, halo-substituted-Ci-4 alkyl, or C3-.7 cycloalkyl
  • Rl8 is C ⁇ _ ⁇ o alkyl, C3-.7 cycloalkyl, heterocyclyl, aryl, aryl ⁇ _ ⁇ oalkyl, heterocyclyl, heterocy clyl-C 1 _ 1 oalkyl, heteroaryl or heteroaryl 1 _ 1
  • R2 is a substituted alkyl derivative. It is recognized that the first methylene carbon in this chain is a tertiary carbon, and it will contain one hydrogen moiety. This methylene group will have has two additional substituents, an R22 moiety and an A moiety, -C(H)(A)(R22)- Both A and R22 m y not be unsubstituted C1 0 alkyl moieties.
  • R2 is a -C(AAj)(A) moiety, wherein AAj is the
  • R22 moiety but is specifically the side chain residue (R) of an amino acid, as is further described herein.
  • A is an optionally substituted C3-.7 cycloalkyl, aryl, heteroaryl, or heterocyclic ring, or A is a substituted C _IQ alkyl moiety.
  • the ring may be substituted independently one or more times, preferably, 1 to 3 times by Ci-io alkyl; halogen; halo substituted Ci-io alkyl, such as CF3; (CR ⁇ oR2 ⁇ )tORn; (CR ⁇ oR2 ⁇ )t Rl3Rl4, especially amino or mono- or di-C ⁇ _4 alkylamino; (CRioR2 ⁇ )tS(O) m Ri8, wherein m is 0, 1 or 2; SH; NRioC(Z)R3 (such NHCO(CMO alkyl)); or NRioS(O) m R8 (such as NHSO2(Ci-io alkyl)).
  • t is 0, or an integer of 1 to 4.
  • A is an optionally substituted cycloalkyl it is as defined below with the R22 substitution.
  • the ring is preferably a morpholino, pyrrolidinyl, piperazinyl or a piperidinyl ring.
  • A is an optionally substituted aryl moiety, it is preferably a phenyl ring.
  • A is an optionally substituted heteroaryl ring, it is as defined below in the definition section.
  • the alkyl chain may be straight or branched. The chain is substituted independently 1 or more times, preferably 1 to 3 times by halogen, such as fluorine, chlorine, bromine or iodine; halosubstituted Ci-io alkyl, such as CF3; C3-7 cycloalkyl, Ci-io alkoxy, such as methoxy or ethoxy; hydroxy substituted Ci-io alkoxy; halosubstituted Ci_io alkoxy, such as OCF2CF2H; OR ⁇ ; S(O)mR ⁇ g (wherein m is 0, 1 or 2); NR13R14; C(Z)NRi3Ri4;
  • A is a C3--7 cycloalkyl, or a C ⁇ .g alkyl, more preferably a C ⁇ _2 alkyl, i.e. a methylene or ethylene moiety, more preferably a methylene moiety which is substituted by one of the above noted groups.
  • A when A is a C ⁇ - 0 alkyl, it is substituted by OR where R ⁇ is preferably hydrogen, aryl or arylalkyl; NR13R14; OC(Z)Rn; or C(Z)ORn. More preferably, A is substituted by ORj ⁇ where R ⁇ ⁇ is hydrogen.
  • R22 i C ⁇ _ ⁇ Q alkyl chain which chain may be straight or branched and which may be optionally substituted independently, one or more times, preferably 1 to 3 times, by halogen, such as fluorine, chlorine, bromine or iodine; halo substituted Cl-10 alkyl; Ci-io alkoxy, such as methoxy or ethoxy; hydroxy substituted C ⁇ _ ⁇ o alkoxy; halosubstituted Ci-io alkoxy, such as OCF2CF2H; ORn; S(O) m R ⁇ s; NR13R14; C(Z)NRi 3 Rl4; S(O) m 'NR ⁇ 3 Rl4; NR 2 3C(Z)R ⁇ ; NHS(O) 2 Rl8; C(Z)R ⁇ ; OC(Z)Rn; C(Z)OR ⁇ ; C(Z)NRnOR 9 ; N(OR 6 )C(Z)NRi 3 Rl4; N(OR 6 )
  • the R22 group may, for instance, be a carboxy, an aldehyde, or an amide, as well as being a substituent off a methylene unit, such as carbamoylmethyl, or acetamidomethyl.
  • R22 is a C ⁇ - unsubstituted or substituted alkyl group, such as a C1.3 alkylene, such as methyl, ethyl or isopropyl, or a methylene or ethylene moiety substituted by one of the above noted moieties, or as noted above those substituent groups which contain a carbon may substitutent for the first methylene unit of the alkyl chain, such as carboxy, C(O)ORj ⁇ , C(O)NRi3Ri4, or R22 is an optionally substituted aryl group, such as a benzyl or phenethyl.
  • R22 can be an optionally substituted alkyl group, or R22 can be C(Z)OR ⁇ 1, C(Z)NR ⁇ iOR9, C(Z)R ⁇ 1,
  • R22 is a C ⁇ .g unsubstituted or substituted alkyl group, more preferably a C ⁇ _2 alkylene chain, such as a methylene or ethylene moiety, more preferably methylene.
  • the alkyl chain is substituted by OR ⁇ ⁇ , where Rj ⁇ is preferably hydrogen, aryl or arylalkyl; S(O)mRi8, where m is 0 and R ⁇ is a C ⁇ . ⁇ alkyl; or an optionally substituted aryl, i.e. a benzyl or phenethyl moiety. More preferably, R22 i phenyl, benzyl, CH2OH, or CH2-O-aryl.
  • one or both of A and R22 contain hydroxy moieties, such as in C ⁇ .g alkyl OR ⁇ , wherein ⁇ is hydrogen, i.e.CH ⁇ CF- ⁇ OH.
  • AA ⁇ is the (R) side chain residue of an amino acid
  • it is a C ⁇ _ alkyl group, which may be straight or branched.
  • the R residue term is for example, CH3 for alanine, (CH 3 ) 2 CH- for valine, (CH 3 )2CH-CH2-for leucine, phenyl-CH 2 - for phenylalanine, CH3-S-CH2-CH-2- for methionine, etc.
  • All generally recognized primary amino acids are included in this groups, such as but not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, hydroxylysine, methylhistidine, and other naturally occurring amino acids not found in proteins, such as ⁇ -alanine, ⁇ -aminobutyric acid, homocysteine, homoserine, citrulline, ornithine, canavanine, djenkolic acid, and ⁇ - cyanoalanine, or other naturally occurring non-mammalian amino acids.
  • AAj is the residue of phenylalanine, or alanine.
  • A is a hydroxy substituted C ⁇ _ ⁇ o alkyl
  • R22 is a alkyl or a hydroxy substituted C ⁇ _ ⁇ Q alkyl.
  • a preferred compound for use herein is l-(l,3-Dihydroxyprop-2-yl)-4-(4- fluorophenyl)-5-(2-phenoxypyrimidin-4-yl)imidazole, or a pharmaceutically acceptable salt thereof.
  • Suitable compounds for use herein include but are not limited to, tr ⁇ n-y- l-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4- yl]imidazole; l-(4-Piperidinyl)-4-(4-fluorophenyl)-5-(2-methoxy-4- pyrimidinyl)imidazole; or (4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4- pyridyl)-imidazole.
  • the daily oral dosage regimen will be from about 0J to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg/kg, more preferably from about 0.5 mg to 15mg.
  • the daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg.
  • the daily topical dosage regimen will preferably be from 0J mg to 150 mg, administered one to four, preferably two or three times daily.
  • the daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day.
  • the novel use of CSAID compounds herein may also be used in association with the veterinary treatment of mammals, other than humans, in need of such inhibition of CSBP/p38 or cytokine inhibition.
  • the CSBP/p38 inhibitor may also be administered with a second therapeutic agent, such as a generally accepted non-sedating antihistamines, such as loratadine (Claritin®), descarboethoxyloratadine (DCL), fexofenadine (Allegra®), and cetirizine hydrochloride (Zyrtec®) etc.; a steroid, such as dexamethasone, prednisone, or prenisolone, etc.; various antibiotics, such as the quinolones, cephalosporins, ⁇ -lactamase inhibitors, etc.; anti-inflammatory agents, such as an NSAID, a COX-1 or COX-2 inhibitor, ASA, or indomethacin, etc.
  • a second therapeutic agent such as a generally accepted non-sedating antihistamines, such as loratadine (Claritin®), descarboethoxyloratadine (DCL),
  • compositions may be administered sequentially, in combination with, or contemporaneously (concomitant use) with a CSAID agent.
  • administration route of the second agent may also differ from that of the CSAID agent, and hence the dosing schedule may vary accordingly.
  • Cetirizine HC1 manufacture and dosing is described in US Patent 4,525,358; fexofenadine manufacture and dosing is described in US Patents 4,524,129; US 5,375,693; US 5,578,610; US 5,855,912; US 5,932,247; and US 6,037,353.
  • Loratadine and DCL manufacture and dosing are described in US patent 4,282,233; US 4,371,516; US 4,659,716; US 4,863,931; US 5,314,697; and US 5,595,997.
  • CSPB/p38 inhibitor may be administered systemically or non- systemically, such as orally, bucally, topically (intranasal) or via inhalation (aerosol), or both topically and via inhalation.
  • a second therapeutic agent may also be administered by any suitable means, including parenteral, suppository, etc. which means of administration is not necessarily by the same route, nor concurrent therewith.
  • topically shall include non-systemic administration. This includes the application of a compound externally to the epidermis or the buccal cavity and/or the instillation of such a compound into the ear, eye and nose.
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration, subcutaneous intranasal, intrarectal, or intravaginal.
  • the optimal quantity and spacing of individual dosages of a CSBP/p38 inhibitor will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a CSBP/p38 inhibitor given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. BIOLOGICAL EXAMPLES
  • a murine model of cigarette smoke inhalation was developed to explore a relationship to leukocyte trafficking and lung chemokine and cytokine production.
  • Balb/c mice are exposed to smoke generated from commercial unfiltered cigarettes for a specified period of time and samples are obtained at varying times during the post-exposure. This model is demonstrated in greater detail as shown below, in contrast to other smoke extract models known in the art.
  • Cigarette Smoke Exposure Model A model of cigarette smoke exposure in the mouse was established in which mice were placed 6 at a time into a small animal plexiglass dosing chamber attached to a peristaltic pump whose intake was connected to a holder for a commercial unfiltered cigarette (Lucky StrikeTM). Along with fresh air, smoke was delivered into the chamber until the cigarette was consumed (approximately 5 minutes). Varying numbers of cigarettes (2-4 per day, 2-3 hr apart) were utilized for 1-3 consecutive days. Animals were euthanized by pentobarbital overdose approximately 18 hours after the final exposure.
  • Bronchoalveolar lavage with phosphate-buffered saline was performed for inflammatory cell enumeration, and BAL aliquots and lungs were frozen for cytokine analysis.
  • Smoke exposure resulted in time- and cigarette number-related increases in airway neutrophils, and lung chemokine (KC) and cytokine (IL-6) content.
  • KC lung chemokine
  • IL-6 cytokine
  • mice are treated with the p38 kinase inhibitor, trans-l-(4- Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yl]imidazole), also referred to as Compound I herein (30 mg/kg, p.o. b.i.d.) which resulted in reduction in lung KC (a murine homologue of IL-8) levels assessed 1 day after exposure (prior to neutrophilia), and attenuated airway neutrophilia and lung IL-6 levels assessed following 3 days of cigarette exposure.
  • Compound I trans-l-(4- Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yl]imidazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une nouvelle utilisation d'un inhibiteur de CSBP/p38 pour le traitement et la prophylaxie de pathologies induites par la fumée et se manifestant par une inflammation chronique des poumons.
EP01987743A 2000-10-19 2001-10-19 Utilisation d'inhibiteurs de p38 pour le traitement de troubles dus a l'inhalation du tabac Withdrawn EP1337250A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24156800P 2000-10-19 2000-10-19
US241568P 2000-10-19
PCT/US2001/050429 WO2002032862A2 (fr) 2000-10-19 2001-10-19 Utilisation d'inhibiteurs de p38 pour le traitement de troubles dus a l'inhalation du tabac

Publications (1)

Publication Number Publication Date
EP1337250A2 true EP1337250A2 (fr) 2003-08-27

Family

ID=22911223

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01987743A Withdrawn EP1337250A2 (fr) 2000-10-19 2001-10-19 Utilisation d'inhibiteurs de p38 pour le traitement de troubles dus a l'inhalation du tabac

Country Status (4)

Country Link
EP (1) EP1337250A2 (fr)
JP (1) JP2004511542A (fr)
AU (1) AU2002231283A1 (fr)
WO (1) WO2002032862A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709965A3 (fr) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methode pour le traitement des maladies reliées au cytokine
MXPA04009605A (es) * 2002-04-05 2005-01-11 Boehringer Ingelheim Pharma Metodo para tratar una hipersecrecion de mucosidad.
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
WO2006137421A1 (fr) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent pour administration topique
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
CN109557254B (zh) * 2018-11-14 2021-08-03 云南中烟工业有限责任公司 一种建立标准化卷烟烟气小鼠口鼻暴露方法的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235760B1 (en) * 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
JP2002517486A (ja) * 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0232862A2 *

Also Published As

Publication number Publication date
WO2002032862A3 (fr) 2002-08-22
AU2002231283A1 (en) 2002-04-29
JP2004511542A (ja) 2004-04-15
WO2002032862A2 (fr) 2002-04-25

Similar Documents

Publication Publication Date Title
EP1337255A2 (fr) Utilisation d'inhibiteurs p38 pour le traitement de toux inflammatoire
Dunford et al. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells
WO2001019322A2 (fr) Utilisation de csaids contre l'infection par rhinovirus
Lee et al. Role of AMP-activated protein kinase (AMPK) in smoking-induced lung inflammation and emphysema
DE502005010170D1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
ECSP077232A (es) Derivados de triazolopridinilsulfanilo como inhibidores de quinasa map p38
KR20200058606A (ko) 면역-관련 및 염증성 질환의 치료
SE0200356D0 (sv) Novel use
NO20071988L (no) Kjemiske forbindelser
JP2008528468A5 (fr)
RU2014108885A (ru) Ингибирование транзиторного рецепторного потенциала ионного канала trpa1
EP1337250A2 (fr) Utilisation d'inhibiteurs de p38 pour le traitement de troubles dus a l'inhalation du tabac
RU2009126633A (ru) Монофосфатные соединения, способ их получения, аэрозольный препарат (варианты) и способ профилактики и/или лечения бронхостеноза посредством указанных соединений
ATE390415T1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
AU2005203706B2 (en) N-phenylbenzamide derivatives as drugs for the treatment of COPD
EA200800183A1 (ru) Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения
US20090209560A1 (en) Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
KR20040007485A (ko) 알레르기성 질환과 같은 비만세포계 질병에 대한ｎ-페닐-2-피리미딘아민의 용도
Sun et al. Theophylline and dexamethasone in combination reduce inflammation and prevent the decrease in HDAC2 expression seen in monocytes exposed to cigarette smoke extract
NI200700039A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38.
US20040092532A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
US20040097473A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
JP2021191804A (ja) 二重ｐｉ３ｋデルタ‐ガンマキナーゼ阻害剤及びコルチコステロイドを含む治療方法及び組成物
CN101951910B (zh) 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
Asano Group 2 Innate Lymphoid Cells and Asthma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030516

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080503